Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 51,000 shares, an increase of 351.3% from the October 31st total of 11,300 shares. Based on an average daily trading volume, of 600 shares, the short-interest ratio is currently 85.0 days.

Shares of Genmab A/S stock opened at $395.92 on Friday. The stock has a 50 day moving average of $437.39 and a 200 day moving average of $436.41. Genmab A/S has a 12 month low of $299.08 and a 12 month high of $500.92. The firm has a market cap of $25.88 billion, a PE ratio of 56.56 and a beta of 0.87.

About Genmab A/S

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.

Featured Story: Asset Allocation and Your Retirement

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.